Replies to post #96813 on Biotech Values

[turtlepower]

Ipilimumab - I agree with you about OS. However the PFS, DCR % and the BORR% appear to indicate that gp100 may have had an adverse impact.

http://abstract.asco.org/AbstView_74_44173.html

[exwannabe]

Re: ipilimab control arm.

"This question is addressed by the comparison between the two Ipilimumab arms (Ipi monotherapy vs Ipi+gp100), where the hazard ratio was 1.04. If gp100 were significantly toxic and thereby reducing survival in the combination arm, the survival difference between the combo arm and the mono arm would not have turned out to be minuscule."

A 3 arm trial of a toxin and its antidote could show the same pattern.